1. Build a Strong Employer BrandFirst up, let’s talk about your employer brand. Think of it as your company’s personality and reputation. In Japan’s competitive pharmaceutical and medical device industry, it’s crucial to stand out. You need to showcase your…
Nippon Kayaku took a pass on the listing of Portrazza (necitumumab), an anti-EGFR antibody it licensed from Eli Lilly, in September as it is “still communicating” with regulators towards its manufacturing and sales, a company spokesperson told Jiho. Lilly obtained…
To read the full story
Related Article
BUSINESS
- Otsuka Achieves 2-Digit Growth Driven by Core Products
February 17, 2025
- Restore Vision Launches Clinical Study of Optogenetic Gene Therapy
February 17, 2025
- Darzquro Filed for High-Risk Smoldering MM in Japan: J&J
February 17, 2025
- Nxera Founder Tamura to Bow Out from Board
February 17, 2025
- Kerendia Filed for Chronic Heart Failure in Japan: Bayer
February 17, 2025
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…